Innoviva Q3 2026 Revenue Down Modestly On Slower Royalty Sales
Innoviva reported modestly lower Q3 2026 revenue as strong growth in innovative therapies was offset by lower royalty revenue, while continuing to repurchase shares and launch new antibiotics.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed